

INOVIQ 30 JUNE 2026 APPENDIX 4C

- Expanded clinical study of the EXO-OC™ test could not be completed due to unsuitability of samples sourced from international biobanks
- Future EXO-OC™ clinical validation studies expected to use single-site biobank, nested prospective or real-world sample evaluation in collaboration with a laboratory partner or CRO
- Optimisation of the EXO-OC™ algorithm in the previously tested 500-sample dataset achieved improved diagnostic performance with 92.3% sensitivity for stage I/II ovarian cancer, 92.5% sensitivity for all-stages and 98% specificity in healthy controls and benign gynaecological disease
- CAR-exosomes demonstrated strong *in vitro* tumour-killing activity in ovarian cancer cell lines eliminating up to 90% of ovarian cancer cells within 48 hours
- INOVIQ is progressing manufacturing readiness, including GMP cell sourcing, CDMO selection and CAR-exosome optimisation
- Strong cash position of A\$9.353m cash at 30 June 2026 and disciplined capital focus

Melbourne, Australia, 13 July 2026: INOVIQ Limited (ASX:IIQ) (INOVIQ or the **Company**), a biotechnology company developing next-generation exosome-based diagnostics and therapeutics, today released its 30 June 2026 Appendix 4C confirming cash balances at 30 June 2026 of \$9.353m.

INOVIQ remains committed to commercialising the EXO-OC™ test, initially as a LDT in the US for early detection of ovarian cancer, before further developing the test as an IVD for screening of ovarian cancer.

INOVIQ Chairman Peter Gunzburg said: “Board and management share the disappointment and frustration with the results from our latest study. This relates to an issue with samples supplied by biobanks rather than to an underlying issue with the test itself. We firmly believe the validation of our test can be completed to the necessary industry standards and continue to work towards that. The cost of the samples related to the setback is approximately \$850k, with FY26 project spend totalling \$1.216m, leaving us with cash of \$9.35m at 30 June 2026.”

The Company is hosting an online Investor Briefing on Tuesday, 14 July 2026 at 11am AEST to discuss the study outcome, key findings from the retrospective study, the actions being taken to advance development of EXO-OC™ and the pathway to commercialisation, followed by an investor Q&A. Registration: [click here](#).

Operating cash receipts during the quarter included:

- \$138k from EXO-NET and hTERT sales during the quarter (Mar-26 qtr: \$62k); and
- \$125k of bank interest (Mar-26 qtr: \$96k).

Net cash used in operating activities for the quarter was \$2,516k, comprising:

- Research and Development (R&D) expenditure of \$1,503k (Mar-26 qtr: \$1,078k) driven by ongoing EXO-OC clinical validation sample acquisition and exosome therapeutic program costs;
- Non-R&D staff costs of \$426k (Mar-26 qtr: \$408k); and
- Administration, corporate and leased asset costs of \$799k (Mar-26 qtr: \$387k) increase attributed to annual insurance program costs.

Payments in section 6.1 of the accompanying Appendix 4C relate to Director fees and superannuation paid during the quarter.

Authorised for release by the INOVIQ Limited Board of Directors.

FURTHER INFORMATION

Dr Leearne Hinch

Chief Executive Officer

E lhinch@inoviq.com

M +61 400 414 416

Peter Gunzburg

Chairman

E peter.gunzburg@gmail.com

M +61 412 927 773

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

INOVIQ LIMITED

ABN

58 009 070 384

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	138	463
1.2 Payments for		
(a) research and development (<i>including allocated staff costs</i>)	(1,503)	(4,430)
(b) advertising and marketing	(22)	(222)
(c) product manufacturing and operating costs	(27)	(68)
(d) staff costs (<i>other than R&D staff</i>)	(426)	(1,590)
(e) administration and corporate costs	(752)	(2,177)
(f) leased assets	(47)	(179)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	125	397
1.5 Interest and other costs of finance paid	(4)	(21)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	1,268
1.8 Other	-	-
1.9 Net cash from / (used in) operating activities	(2,516)	(6,559)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(g) entities	-	-
(h) businesses	-	-
(i) property, plant and equipment	(30)	(169)
(j) investments	-	-
(k) intellectual property	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(l) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other	-	-
2.6	Net cash from / (used in) investing activities	(30)	(169)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	10,200
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(597)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(9)	(38)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(9)	9,565

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	11,899	6,521
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,516)	(6,559)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(30)	(169)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(9)	9,565
4.5	Effect of movement in exchange rates on cash held	9	(5)
4.6	Cash and cash equivalents at end of period	9,353	9,353

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,103	899
5.2	Call deposits	8,250	11,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	9,353	11,899

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

92

-

Payments in 6.1 relate to Director fees and superannuation paid during the quarter.

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
-	-
20	-
-	-
-	-

7.5 **Unused financing facilities available at quarter end**

20

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Relates to the corporate credit card facility with the National Australia Bank.

8. Estimated cash available for future operating activities

\$A'000

8.1	Net cash from / (used in) operating activities (Item 1.9)	(2,516)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	9,353
8.3	Unused finance facilities available at quarter end (Item 7.5)	20
8.4	Total available funding (Item 8.2 + Item 8.3)	9,373
8.5	Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	3.7

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 13 July 2026

Authorised by: The Board of Directors

Authorised for release by Company Secretary – Mark Edwards
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.